Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of Prophylactic and Therapeutic Anticoagulation in Hospitalized COVID-19 Patients: A Randomized Clinical Trial

  • By

  • Mahir Karakas

  • Shiva Sophia Nicolay

  • Dominic Wichmann

  • Stefan Schmiedel

  • Marylyn M. Addo

  • Anna Nosko

  • Natalie Lund

  • Apurva Shrivastava

  • Isabell Pink

  • Daniel Duerschmied

  • Nadine Gauchel

  • Elisabeth Schnoy

  • Ulrich-Frank Pape

  • Berthold Bein

  • Philipp Brasch

  • Dirk Arnold

  • Katrin Maevers

  • Sebastian Rasch

  • Johanna Erber

  • Tobias Lahmer

  • Tanja Zeller

  • Florian Langer

  • Ann-Kathrin Ozga

  • Anna Suling

  • Antonia Zapf

  • Dominik Jarczak

  • Stefan Kluge

  • September 23, 2026

Share

Clinical Scorecard: Comparative Analysis of Prophylactic and Therapeutic Anticoagulation in Hospitalized COVID-19 Patients: A Randomized Clinical Trial

At a Glance

CategoryDetail
ConditionCOVID-19 coagulopathy
Key MechanismsProinflammatory state, endothelial dysfunction, hypercoagulability
Target PopulationHospitalized patients with confirmed COVID-19
Care SettingMulticenter hospital trial

Key Highlights

  • Therapeutic-dose anticoagulation may lower mortality compared to prophylactic dosing.
  • Intermediate-dose regimens remain inconclusive in efficacy.
  • Comprehensive assessment of thromboembolic events was conducted.

Guideline-Based Recommendations

Diagnosis

  • Confirmed COVID-19 diagnosis via PCR, antigen test, or IgM test.

Management

  • Therapeutic anticoagulation with LMWH or fondaparinux during hospitalization, followed by edoxaban.

Monitoring & Follow-up

  • Systematic assessment of thromboembolic events, including serial duplex ultrasonography.

Risks

  • Increased risk of venous thromboembolism and arterial thromboembolism.

Patient & Prescribing Data

Patients hospitalized with COVID-19, including ICU and non-ICU.

Prophylactic-dose anticoagulation is used to prevent venous thromboembolism.

Clinical Best Practices

  • Conduct thorough eligibility assessments for anticoagulation.
  • Utilize a randomized controlled trial design for evaluating treatment efficacy.

Related Resources & Content

Original Source(s)

Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19: A Randomized Clinical

  • by Mahir Karakas, Shiva Sophia Nicolay, Dominic Wichmann, Stefan Schmiedel, Marylyn M. Addo, Anna Nosko, Natalie Lund, Apurva Shrivastava, Isabell Pink, Daniel Duerschmied, Nadine Gauchel, Elisabeth Schnoy, Ulrich-Frank Pape, Berthold Bein, Philipp Brasch, Dirk Arnold, Katrin Maevers, Sebastian Rasch, Johanna Erber, Tobias Lahmer, Tanja Zeller, Florian Langer, Ann-Kathrin Ozga, Anna Suling, Antonia Zapf, Dominik Jarczak, Stefan Kluge

  • September 23, 2026

Related Content

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

  • October 12, 2026

  • 3 min
When Pathology Met a National Crisis

A personal account of how laboratory expertise can inform, reassure, and educate during a public emergency

“A long bristling road full of adventure, full of discovery” gene therapy approaches in transfusion-dependent thalassemia: The EHA-EBMT consensus paper